The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database.
about
A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdoseSeizures associated with therapeutic doses of venlafaxine and trimipramine.Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data.Neuropharmacology of venlafaxine.Efficacy of venlafaxine in the treatment of severe depression.Efficacy of venlafaxine in geriatric depression.Fatality related to a 30-g venlafaxine overdose.Accelerated hypertension after venlafaxine usageCardiovascular and neurological toxicity of venlafaxine.Antidepressant-induced liver injury.Clinical use of antidepressant therapy and associated cardiovascular riskDo antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study.A comparison of venlafaxine and SSRIs in deliberate self-poisoningVenlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorderDuloxetine-induced hypomania: case report and brief review of the literature on SNRIs-induced mood switching.Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.Pharmacological management of unipolar depression.A review of the adverse effects and safety of noradrenergic antidepressants.Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety.Venlafaxine as the 'baby ecstasy'? Literature overview and analysis of web-based misusers' experiences.Two Formulations of Venlafaxine are Bioequivalent when Administered as Open Capsule Mixed with Applesauce to Healthy Subjects.Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate.An organic psychosis due to a venlafaxine-propafenone interaction.Proconvulsant effects of high doses of venlafaxine in pentylenetetrazole-convulsive rats.Venlafaxine poisoning complicated by a late rise in creatine kinase: two case reports.Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.Anticholinergic-type effects following a pediatric venlafaxine overdose.Hepatitis associated with low-dose venlafaxine for postmenopausal vasomotor symptoms.Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.Is There a Potential of Misuse for Venlafaxine and Bupropion?
P2860
Q24606269-72D34303-EA55-4896-9F97-8CED3142299AQ31805799-CD9C0D7E-316B-4308-8660-653B2F522D1BQ33815059-641A28DD-08CE-4A30-BB0B-0DFA10FEE7E1Q34093686-C68E2EDF-C680-4C07-B5A6-67B456E166C1Q34093702-486B3E88-6CE5-4FEC-B01C-844C063AF518Q34093713-791F756B-FDA7-45F6-9A82-25DCEB296EA2Q34286141-C6EA5057-FFAE-45DA-A3E2-1B545FF22C95Q34311469-19FF6FF8-59FD-41A0-9D35-1329F47CB4C8Q34503904-0D008957-95AD-4045-BFBC-9AD1479DFB35Q34580845-B7042973-A0E3-4FCF-8010-8B1E1501B3D3Q36184863-01B23964-8885-4530-BC92-093B6E2E87C4Q36374021-7D34B5F0-3D77-4362-BC2A-5C326AD947E0Q36549123-F69684D2-339C-44CA-B35B-EB2A68133D33Q37010434-CE22BB5A-34DC-4318-939B-AFF3788D7861Q37194212-640AD4C5-64D4-484B-B5CC-6195E59A4306Q37625519-4953A53A-09E3-46DD-9261-5D10B486602DQ37808483-6BD61324-F7B0-404D-BB55-5328B9662A3CQ38099042-591AEEC1-C87D-4550-9BC5-A14A32061135Q38115737-5344AC0C-6BD1-4AA9-B243-A30D0EB29BC2Q38367401-E33A7863-BD40-4CA5-9B9C-E8DAD60BAAACQ38555616-8FCCD8FE-1615-486E-BC71-6A69F141F89CQ42096559-F10A0242-CB77-4611-A643-07F8C614C8DCQ43235413-BD0E38AA-F3C2-4C98-BE9F-93DB6C4B5F20Q43848135-C284017F-F6C7-4AA1-8508-1426B0824F12Q43956648-82D3F0D8-74B2-4A3C-B51B-A507A992BFF3Q43963699-1E66DE92-4A29-4ABB-ABC5-C1ABB3B91641Q44202388-FB7D8B49-106B-4CDB-89D2-E7A2E66C967CQ46477533-18AB7132-5DB0-462F-AE5B-19A8D2571FBEQ46685294-3D846D2C-3D03-4E6E-8B43-8C07FF45F9E4Q46897991-793F277B-0DD2-4D3C-96CE-853813CF219AQ51902879-A267F41F-BD6B-466B-AEEE-46D7EC5AA85CQ52606203-821B31DB-1F33-43C7-ACFA-71D323A4969F
P2860
The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
The safety and tolerability of ...... the clinical trials database.
@en
type
label
The safety and tolerability of ...... the clinical trials database.
@en
prefLabel
The safety and tolerability of ...... the clinical trials database.
@en
P1476
The safety and tolerability of ...... the clinical trials database.
@en
P2093
Derivan AT
Rudolph RL
P304
54S-59S; discussion 59S-61S
P356
10.1097/00004714-199606002-00011
P407
P433
P577
1996-06-01T00:00:00Z